bims-rebome Biomed News
on Management of bone metastases
Issue of 2026–05–03
five papers selected by
Alberto Selvanetti, Azienda Ospedaliera San Giovanni Addolorata



  1. Neurochirurgie. 2026 Apr 25. pii: S0028-3770(26)00052-4. [Epub ahead of print]72(3): 101818
      The spine is among the most frequent sites of metastatic disease, with an increasing prevalence, leading to increasing rates of surgical interventions. The choice of surgical technique (ranging from minimally invasive techniques, to radical resection), is usually based on expected survival, treatment-related morbidity, and outcome after treatment. A number of scoring systems have been developed to assess the predicted life expectancy of patients with spinal metastasis. Some of the most common predictive scoring systems include: the revised Tokuhashi score, the Tomita score, the modified Bauer score, the revised Katagiri, and the van der Linden scoring system; who are widely used and accepted. While many studies have reviewed the efficacy of historic scoring systems with positive results in many, an increasing amount of studies have shown that the accuracy of historic scoring systems is relatively low, and decreasing over time. The major hypothesis for the decreasing accuracy of these scores is the improved survival associated with new anticancer therapies. More recently, more modern scoring systems have emerged, such as the SORG nomogram, and machine learning algorithms, as well as open access application for clinicians. Even though a greater number of features is needed in order to establish prognosis, most of the features needed can be found in the patient's charts. They have been the subject of numerous studies to externally validate their efficacy, and it was shown that that the SORG Nomogram demonstrated the highest accuracy at predicting 30-day and 90-day survival after surgery. Although emerging scoring systems show promise in predicting survival, none should supplant multidisciplinary consultation when determining the indication for surgical intervention. Survival prediction alone should not serve as the sole justification for surgery, as careful consideration should also be given to the patient's overall clinical condition, psychological well-being, neurological status, and expected prognosis.
    Keywords:  Cancer, review; Prognostic score; Spinal metastasis; Survival
    DOI:  https://doi.org/10.1016/j.neuchi.2026.101818
  2. Int J Cancer. 2026 Apr 27.
      Neurosurgical resection of spinal metastases is an established treatment option for selected patients with advanced malignancies. However, high perioperative morbidity and mortality may further compromise outcomes in this vulnerable population, emphasizing the need to identify modifiable prognostic factors. Perioperative anemia is common and clinically relevant, yet its impact in this setting remains insufficiently studied. This retrospective, single-center study included 279 patients who underwent surgical treatment for spinal metastases between 2013 and 2025. Patients were stratified into three groups based on perioperative hemoglobin levels. Multivariable logistic regression, Cox proportional hazards models, and Kaplan-Meier analyses were used to assess associations between perioperative hemoglobin levels and postoperative complications, local recurrence, recurrence-free survival, and mortality at 1 month and 1 year after surgery. Preoperative anemia was independently associated with an increased risk of hospital-acquired complications (odds ratio [OR] 2.31, 95% confidence interval [CI] 1.35-3.97, p = 0.002), while higher hemoglobin levels showed a protective effect. No significant association was found between perioperative hemoglobin levels and surgical complications (OR 0.73, 95% CI 0.36-1.51, p = 0.400). Postoperative hemoglobin levels and perioperative hemoglobin changes were not significantly associated with complications (OR 1.008, 95% CI 0.990-1.026, p = 0.389) or mortality. One-month and one-year mortality rates were lowest in patients without anemia and highest in those with severe anemia. Our data demonstrate that early identification and optimization of preoperative anemia may reduce postoperative complications and potentially improve survival outcomes in patients undergoing surgery for spinal metastases.
    Keywords:  complications; perioperative hemoglobin; spinal metastasis; surgical treatment
    DOI:  https://doi.org/10.1002/ijc.70513
  3. Neurochirurgie. 2026 Apr 25. pii: S0028-3770(26)00048-2. [Epub ahead of print]72(3): 101814
       BACKGROUND: Management of cervical spine metastases (CSM) is uniquely challenging due to regional biomechanics and neurovascular proximity. This study evaluates surgical strategies, focusing on the shift from radicality to functional preservation and the importance of multidisciplinary integration.
    METHODS: A systematic literature search was conducted across PubMed, MEDLINE, and Google Scholar (2015-2025), using the string "cervical" AND "spine" AND "metastases". From an initial pool of 1134 articles, a multi-stage screening process based on title, abstract, and predefined eligibility criteria was performed. Inclusion was restricted to English-language studies reporting clear functional outcomes. A final selection of 18 high-quality articles was analyzed.
    RESULTS: Strategy is strictly region-dependent: C0-C2 requires posterior fusion to manage translational instability; subaxial (C3-C6) ventral decompression via anterior corpectomy often necessitates posterior reinforcement for torsional control; and cervicothoracic (C7-T1) lesions are best managed via posterior-only long-segment fixation to avoid invasive manubriotomy. Modern "tissue-sparing" tools, such as Separation Surgery, ECT, and Carbon-PEEK implants, significantly enhance the "oncological window" by facilitating safe, high-dose SBRT. Despite a 20% morbidity rate, surgery markedly improves Quality of Life within the first 6 months.
    CONCLUSIONS: Surgical intervention for CSM should prioritize functional restoration and "oncological window" preservation. In patients with favorable performance status, proactive stabilization is justified regardless of tumor aggressiveness, provided that surgical goals remain realistic and a reasonable risk-benefit ratio is maintained within the limits of clinical appropriateness.
    Keywords:  Cervical instability; Cervical spine metastases; Surgical treatment
    DOI:  https://doi.org/10.1016/j.neuchi.2026.101814
  4. In Vivo. 2026 May-Jun;40(3):40(3): 1722-1732
       BACKGROUND/AIM: Although the effects of varying heart doses on overall survival (OS) in curative thoracic radiotherapy have been investigated, their impact in palliative settings remains underexplored. This study aimed to examine the impact of heart dose on OS in patients with bone metastases treated with palliative radiotherapy over a three-year follow-up period.
    MATERIALS AND METHODS: This study included 303 patients who underwent palliative radiotherapy for bone metastases between 2013 and 2022. The primary endpoint was OS, which was evaluated over a fixed three-year follow-up period. To adjust for baseline confounders between patients with and without mean heart dose (MHD) ≥5Gy, we performed 1:1 propensity score matching (PSM) using the following variables: performance status (PS); primary tumor type; number of bone metastases; number of distant metastases (visceral organs, non-regional lymph nodes, and serosal surfaces such as the pleura and peritoneum).
    RESULTS: A total of 108 of 303 patients were included after PSM, with 54 patients each in the groups with and without MHD ≥5 Gy. After matching, the baseline characteristics used as matching variables were well balanced, with no significant differences between the groups according to the chi-square test. Kaplan-Meier analysis demonstrated significantly poorer OS in patients with MHD ≥5 Gy than in those without (p=0.016); annualized event rates for OS were 30.2% and 21.6% in patients with and without MHD ≥5 Gy, respectively.
    CONCLUSION: In propensity score-matched patients receiving palliative, but not curative, radiotherapy, higher MHD was significantly associated with poorer OS over a three-year follow-up period. Furthermore, in the palliative cohort, the MHD level associated with OS may be lower than that in the curative setting.
    Keywords:  Palliative care; bone neoplasms; heart; prognosis; radiotherapy
    DOI:  https://doi.org/10.21873/invivo.14323
  5. Anticancer Res. 2026 May;46(5): 2663-2670
       BACKGROUND/AIM: To evaluate the tolerability and effectiveness of pregabalin for the treatment of opioid-resistant neuropathic pain associated with bone metastases in patients with cancer.
    PATIENTS AND METHODS: This single-center retrospective study reviewed medical records from Kindai University Hospital between 2015 and 2020. Pregabalin tolerability was evaluated based on treatment continuation and the occurrence of adverse events. Effectiveness in pain relief was assessed using changes in the numerical rating scale (NRS) over a 7-35-day observation period, which was specifically defined to exclude the effects of chemotherapy and radiotherapy.
    RESULTS: Among 26 patients with bone metastases who were newly prescribed pregabalin for neuropathic pain refractory to opioids in Group 1, six (23%) discontinued pregabalin because of adverse events, including dizziness and somnolence. All six patients were aged ≥60 years. The median age was higher in the discontinuation group than in the continuation group (74 vs. 61 years). Twelve patients who continued treatment (Group 2) were evaluated for effectiveness. A consistent reduction in NRS scores was observed in eight patients (67%) who continued treatment, with four patients (33%) achieving a 50% or greater reduction in neuropathic pain intensity. Although the maximum pregabalin dose ranged from 50 to 300 mg/day, pain relief was observed in 80% (four of five patients) even at low dosages (50-75 mg/day).
    CONCLUSION: This exploratory study suggests pregabalin may mitigate opioid-resistant neuropathic pain in patients with bone metastases, often at relatively low dosages. However, approximately 20% of patients, particularly older individuals, were intolerant to the medication. Initiating treatment at a low dose may be important for improving tolerability in older patients with cancer.
    Keywords:  Pregabalin; bone metastases; cancer; neuropathic pain; opioid-resistant pain
    DOI:  https://doi.org/10.21873/anticanres.18146